Portfolio company Elektrofi was acquired by Halozyme Therapeutics in November 2025.
Elektrofi is a biotechnology company focused on reformulating biologic therapies for subcutaneous delivery, utilizing its Hypercon microparticle platform technology to enhance patient experience and adherence
Elektrofi is a biotechnology company focused on reformulating biologic therapies for subcutaneous delivery, utilizing its Hypercon microparticle platform technology to enhance patient experience and adherence.